ES2556770T3 - Expresión híbrida y en tándem de proteínas procedentes de Neisseria - Google Patents

Expresión híbrida y en tándem de proteínas procedentes de Neisseria Download PDF

Info

Publication number
ES2556770T3
ES2556770T3 ES10179788.4T ES10179788T ES2556770T3 ES 2556770 T3 ES2556770 T3 ES 2556770T3 ES 10179788 T ES10179788 T ES 10179788T ES 2556770 T3 ES2556770 T3 ES 2556770T3
Authority
ES
Spain
Prior art keywords
patent application
international patent
protein
seq
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10179788.4T
Other languages
English (en)
Inventor
Mariagrazia Pizza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9921633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2556770(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of ES2556770T3 publication Critical patent/ES2556770T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Una composición que comprende las siguientes proteínas: (1) NH2-A-[X-L-]n-B-COOH, en la que n>= 2, X1>= 287, X2>= 953 (2) 961 (3) NH2-A-[X-L-]n-B-COOH, en la que n>= 2, X1>= 936, X2>= 741, en la que 287 es la SEC ID Nº: 3104 del documento WO99/57280 o una proteína que tiene una identidad de secuencia de un 80 % o más con ella, 953 es la SEC ID Nº: 2918 del documento WO99/57280 o una proteína que tiene una identidad de secuencia de un 80 % o más con ella, 961 es la SEC ID Nº: 940 del documento WO99/57280 o una proteína que tiene una identidad de secuencia de un 80 % o más con ella, 936 es la SEC ID Nº: 2884 del documento WO99/57280 o una proteína que tiene una identidad de secuencia de un 80 % o más con ella, 741 es la SEC ID Nº: 2536 del documento WO99/57280 o una proteína que tiene una identidad de secuencia de un 80 % o más con ella, y en la que cada L es una secuencia de aminoácidos engarzadora opcional, A es una secuencia de aminoácidos N-terminal opcional y B es una secuencia de aminoácidos Cterminal opcional.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
5
10
15
20
25
30
35
contra diversas cepas:
2996(B)
MC58(B) NGH38 394/98(B) H44/76(B) F6124(A) BZ133(C) C11(C)
(1)
32000 16000 130000 16000 32000 8000 16000 8000
(2)
256 131000 128 16000 32000 8000 16000 <4
(3)
32000 8000 - - - 8000 - 32000
mezcla
32000 32000 65000 16000 260000 65000 >65000 8000
(X)
4000 4000 1000 1000 >4000 1000 4000 n.d.
’-’ indica que esta cepa no contiene el gen NadA (X) era una combinación de la proteína 287 con vesículas de membrana externa, para comparar
Considerando los ratones individualmente, la mezcla indujo títulos bactericidas elevados y uniformes:
Nº
1 2 3 4 5 6 7 8 9 10
2996
32768 16384 65536 32768 32768 65536 65536 32768 65536 8192
MC58
65536 32768 65536 65536 65536 18192 65536 32768 132768 65536
394/98
65536 4096 16384 4096 8192 4096 32768 16384 8192 16384
Deleción de dominios -961
961 no está presente en la secuencia del genoma del serogrupo A de N. meningitidis [80], aun cuando las regiones circundantes estén conservadas (> 90 %) entre los serogrupos A y B. Las referencias 10 y 11 desvelan formas polimórficas de 961. Se encontró que el gen estaba presente en el 91 % de las cepas del serogrupo B pertenecientes a los linajes hipervirulentos ET-5, ET-37 y el grupo A4, pero estaba ausente en todas las cepas ensayadas del linaje 3. La mayoría de las cepas del serogrupo C ensayadas fueron positivas aunque no perteneciesen a linajes hipervirulentos. Lo mismo ocurrió con las cepas del serogrupo B con serotipos 2a y 2b. Para el serogrupo A, una cepa perteneciente al subgrupo III fue positiva, mientras que las otras dos cepas pertenecientes al subgrupo IV-1 fueron negativas. 961 estaba ausente en N. gonorrhoeae y en las especies comensales N. lactamica y N. cinerea.
Las figuras 1 y 2 muestran dominios en la proteína 961.
Cuando la región anclada (dominio 9) de la proteína 961 se suprime ("961cL") y se expresa en E. coli, la proteína se exporta al periplasma y se segrega en el sobrenadante del cultivo.
Para investigar esto más, se construyeron mutantes de deleción en la región C-terminal de 961 (961cL-Δaro, 961cLΔcc, 961aL, 961aL-Δ1, 961aL-Δ2, 961aL-Δ3) sobre la base de aspectos estructurales (deleciones de residuos aromáticos en los casos del mutante 961cΔaro, y de las regiones de superenrollamiento para los otros). Se analizaron con respecto a expresión y secreción al periplasma y al sobrenadante del cultivo. En todos estos mutantes de deleción, la proteína se produce en gran cantidad, está presente en la fracción periplásmica y se libera al sobrenadante del cultivo.
Referencias
1 -Solicitud de patente internacional WO01/64920.
2 -Solicitud de patente internacional WO01/64922.
3 -Solicitud de patente internacional WO99/24578.
4 -Solicitud de patente internacional WO99/36544.
5 -Solicitud de patente internacional WO99/57280.
6 -Solicitud de patente internacional WO00/22430.
7 -Solicitud de patente internacional WO00/66741.
8 -Solicitud de patente internacional WO00/71574.
9 -Solicitud de patente internacional WO01/04316.
10 -Solicitud de patente internacional PCT/IB02/03396.
11 -Comanducci y col. (2002) J Exp Med 195:1445-1454.
12 -Vaccine Design: subunit & adjuvant approach (1995) Powell y Newman (ISBN: 030644867X).
10
13 -Solicitud de patente internacional WO01/52885.
14 -Bjune y col. (1991) Lancet 338(8775):1093-1096.
15 -Fukasawa y col. (1999) Vaccine 17:295 -2958.
16 -Rosenqvist y col. (1998) Dev. Biol. Stand. 92:323-333.
5 17 -Costantino y col. (1992) Vaccine 10:691-698.
18 -Costantino y col. (1999) Vaccine 17:1251-1263.
19 -Solicitud de patente internacional PCT/IB02/03191.
20 -Watson (2000) Pediatr Infect Dis J 19:331-332.
21 -Rubin (2000) Pediatr Clin North Am 47:269-285, v.
22 -Jedrzejas (2001) Microbiol Mol Biol Rev 65:187-207
23 -Solicitud de patente internacional WO93/18150.
24 -Solicitud de patente internacional WO99/53310.
25 -Solicitud de patente internacional WO98/04702.
26 -Bell (2000) Pediatr Infect Dis J 19:1187-1188. 15 27 -Iwarson (1995) APMIS 103:321-326.
28 -Gerlich y col. (1990) Vaccine 8 Supl: S63-68 y 79-80.
29 -Hsu y col. (1999) Clin Liver Dis 3:901-915.
30 -Gustafsson y col. (1996) N. Engl. J. Med. 334:349-355.
31 -Rappuoli y col. (1991) TIBTECH 9:232-238.
32 -Vaccines (1988) eds. Plotkin y Mortimer. ISBN 0-7216-1946-0.
33 -Del Guidice y col. (1998) Molecular Aspects of Medicine 19:1-70.
34 -Solicitud de patente internacional WO00/02606.
35 -Kalman y col. (1999) Nature Genetics 21:385-389.
36 -Read y col. (2000) Nucleic Acids Res 28:1397-406. 25 37 -Shirai y col. (2000) J. Infect. Dis. 181(Suppl 3):S524-S527.
38 -Solicitud de patente internacional WO99/27105.
39 -Solicitud de patente internacional WO00/27994.
40 -Solicitud de patente internacional WO00/37494.
41 -Solicitud de patente internacional WO99/28475.
42 -Ross y col. (2001) Vaccine 19:4135-4142.
43 -Sutter y col. (2000) Pediatr Clin North Am 47:287-308.
44 -Zimmerman y Spann (1999) Am Fam Physician 59:113-118, 125-126.
45 -Dreesen (1997) Vaccine 15 Supl: S2-6.
46 -MMWR Morb Mortal Wkly Rep 1998 Jan 16; 47(1):12, 19. 35 47 -McMichael (2000) Vaccine 19 Supl 1:S101-107.
48 -Schuchat (1999) Lancet 353(9146):51-6.
49 -Documento WO02/34771.
50 -Dale (1999) Infect Dis Clin North Am 13:227-43, viii.
51 -Ferretti y col. (2001) PNAS USA 98: 4658-4663.
52 -Kuroda y col. (2001) Lancet 357(9264):1225-1240; véanse también las páginas 1218-1219.
53 -Ramsay y col. (2001) Lancet 357(9251):195-196.
54 -Lindberg (1999) Vaccine 17 Supl 2:S28-36.
55 -Buttery y Moxon (2000) J R Coll Physicians Lond 34:163-168.
56 -Ahmad y Chapnick (1999) Infect Dis Clin North Am 13:113-133, vii. 45 57 -Goldblatt (1998) J. Med. Microbiol 47:563-567.
58 -Patente europea 0 477 508.
59 -Patente de Estados Unidos 5.306.492.
60 -Solicitud de patente internacional WO98/42721.
61 -Conjugate Vaccines (eds. Cruse y col.) ISBN 3805549326, particularmente vol. 10:48-114.
62 -Hermanson (1996) Bioconjugate Techniques ISBN: 0123423368 o 012342335X.
63 -Solicitud de patente europea 0372501.
64 -Solicitud de patente europea 0378881.
65 -Solicitud de patente europea 0427347.
66 -Solicitud de patente internacional WO93/17712. 55 67 -Solicitud de patente internacional WO98/58668.
68 -Solicitud de patente europea 0471177.
69 -Solicitud de patente internacional WO00/56360.
70 -Solicitud de patente internacional WO00/61761.
71 -Robinson y Torres (1997) Seminars in Immunology 9:271-283.
72 -Donnelly y col. (1997) Annu Rev Immunol 15:617-648.
73 -Scott-Taylor y Dalgleish (2000) Expert Opin Investig Drugs 9:471-480.
74 -Apostolopoulos y Plebanski (2000) Curr Opin Mol Ther 2:441-447.
75 -Ilan (1999) Curr Opin Mol Ther 1:116-120.
76 -Dubensky y col. (2000) Mol Med 6:723-732. 65 77 -Robinson y Pertmer (2000) Adv Virus Res 55:1-74.
78 -Donnelly y col. (2000) Am JRespir Crit Care Med 162(4 Pt 2): S 190-193.
11

Claims (1)

  1. imagen1
ES10179788.4T 2001-09-06 2002-09-06 Expresión híbrida y en tándem de proteínas procedentes de Neisseria Expired - Lifetime ES2556770T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0121591 2001-09-06
GBGB0121591.2A GB0121591D0 (en) 2001-09-06 2001-09-06 Hybrid and tandem expression of neisserial proteins

Publications (1)

Publication Number Publication Date
ES2556770T3 true ES2556770T3 (es) 2016-01-20

Family

ID=9921633

Family Applications (3)

Application Number Title Priority Date Filing Date
ES10179788.4T Expired - Lifetime ES2556770T3 (es) 2001-09-06 2002-09-06 Expresión híbrida y en tándem de proteínas procedentes de Neisseria
ES10179755.3T Expired - Lifetime ES2523365T3 (es) 2001-09-06 2002-09-06 Expresión híbrida y en tandem de proteínas de Neisseria
ES02777592T Expired - Lifetime ES2357503T3 (es) 2001-09-06 2002-09-06 Expresión híbrida y en tandem de proteínas de neisseria.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES10179755.3T Expired - Lifetime ES2523365T3 (es) 2001-09-06 2002-09-06 Expresión híbrida y en tandem de proteínas de Neisseria
ES02777592T Expired - Lifetime ES2357503T3 (es) 2001-09-06 2002-09-06 Expresión híbrida y en tandem de proteínas de neisseria.

Country Status (18)

Country Link
US (6) US8980277B2 (es)
EP (4) EP2829549A3 (es)
JP (4) JP4511832B2 (es)
CN (2) CN100390196C (es)
AT (1) ATE496063T1 (es)
AU (2) AU2002339217B2 (es)
BR (1) BR0212363A (es)
CA (1) CA2459816C (es)
CY (2) CY1113218T1 (es)
DE (1) DE60238993D1 (es)
DK (3) DK2360176T3 (es)
ES (3) ES2556770T3 (es)
GB (1) GB0121591D0 (es)
MX (2) MXPA04002216A (es)
NZ (3) NZ537976A (es)
PT (3) PT2360176E (es)
RU (2) RU2339646C2 (es)
WO (1) WO2003020756A2 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2278011A3 (en) * 1998-01-14 2012-03-07 Novartis Vaccines and Diagnostics S.r.l. Neisseria meningitidis antigens
AU761780B2 (en) 1998-05-01 2003-06-12 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
EP1228217B1 (en) 1999-04-30 2012-11-21 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
MXPA01011867A (es) * 1999-05-19 2002-05-06 Chiron Spa Composiciones neisseriales de combinacion.
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
AU784203B2 (en) 1999-10-29 2006-02-23 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2275129A3 (en) * 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
JP4763210B2 (ja) 2000-02-28 2011-08-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ナイセリアのタンパク質の異種発現
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
ATE469915T1 (de) 2001-07-27 2010-06-15 Novartis Vaccines & Diagnostic Antikörper gegen das meningokokken adhäsin app
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7838015B2 (en) 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP2255826B1 (en) * 2002-08-02 2016-04-13 GlaxoSmithKline Biologicals S.A. Neisserial vaccine compositions comprising a combination of antigens
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
PT2353608T (pt) 2002-10-11 2020-03-11 Novartis Vaccines And Diagnostics S R L Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas
AU2003288660A1 (en) 2002-11-15 2004-06-15 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
SI1961426T1 (sl) * 2003-10-02 2011-10-28 Novartis Ag Kombinirana cepiva proti meningitisu
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0415160D0 (en) * 2004-07-06 2004-08-11 Chiron Srl Inhibitors of bacterial infection
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
CN101180312A (zh) 2005-02-18 2008-05-14 诺华疫苗和诊断公司 来自尿路病原性大肠杆菌的免疫原
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US20110008279A1 (en) * 2005-12-06 2011-01-13 Vega Masignani Methods and Compositions Relating to Adhesins as Adjuvants
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
CN101951949B (zh) 2007-10-19 2013-10-02 诺华股份有限公司 脑膜炎球菌疫苗制剂
EP3263591B1 (en) 2008-02-21 2019-03-27 GlaxoSmithKline Biologicals S.A. Meningococcal fhbp polypeptides
NZ588191A (en) 2008-03-03 2012-06-29 Irm Llc Compounds and compositions as tlr activity modulators
ES2557282T3 (es) * 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
CA2726512A1 (en) * 2008-06-09 2009-12-17 Novartis Ag Antibodies against neisserial factor h binding protein
WO2010070453A2 (en) * 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
PT2411048T (pt) 2009-03-24 2020-07-14 Glaxosmithkline Biologicals Sa Proteína de ligação ao fator h meningocócica com adjuvante
NZ595361A (en) * 2009-04-30 2013-09-27 Childrens Hosp & Res Ct Oak Chimeric factor h binding proteins (fhbp) and methods of use
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
MX2012004850A (es) 2009-10-27 2012-05-22 Novartis Ag Polipeptidos fhbp meningococicos modificados.
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
CN102762206A (zh) 2009-12-15 2012-10-31 诺华有限公司 免疫增强化合物的均匀悬液及其用途
JP5363381B2 (ja) * 2010-03-09 2013-12-11 パナソニック株式会社 プラズマディスプレイパネル
EA023725B1 (ru) 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CA2790167C (en) 2010-03-30 2021-02-09 Children's Hospital & Research Center Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
MX350142B (es) 2010-08-23 2017-08-28 Wyeth Llc * Formulaciones estables de antigenos rlp2086 de neisseria meningitidis.
WO2012032498A2 (en) 2010-09-10 2012-03-15 Novartis Ag Developments in meningococcal outer membrane vesicles
EP3549601B1 (en) 2010-09-10 2021-02-24 Wyeth LLC Non-lipidated variants of neisseria meningitidis orf2086 antigens
CN102028941B (zh) * 2011-02-11 2013-02-13 中国医学科学院医学生物学研究所 一种b群脑膜炎球菌重组蛋白嵌合疫苗及其制备方法
US20140186861A1 (en) * 2011-07-11 2014-07-03 Uvic Industry Partnerships Inc. Soluble treponema pallidum protein tp0453, tp0453-tp0326 fusion protein, and use in syphilis diagnosis
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
JP2015524418A (ja) 2012-07-27 2015-08-24 アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 血管内皮細胞への髄膜炎菌の線毛媒介接着の受容体としてのｃｄ１４７
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
SG11201600334SA (en) * 2013-08-02 2016-02-26 Children S Hospital & Res Ct Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20160127104A (ko) 2014-02-28 2016-11-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 수막구균 fhbp 폴리펩티드
EP4074726A3 (en) 2014-07-23 2022-11-23 Children's Hospital & Research Center at Oakland Factor h binding protein variants and methods of use thereof
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
US20180064801A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
AU2022223712A1 (en) 2021-02-19 2023-10-05 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024030931A1 (en) 2022-08-03 2024-02-08 Sanofi Pasteur Inc. Adjuvanted immunogenic composition against neisseria meningitidis b

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196056B1 (en) * 1985-03-28 1991-05-22 Chiron Corporation Improved expression using fused genes providing for protein product
DE3622221A1 (de) 1986-07-02 1988-01-14 Max Planck Gesellschaft Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen
EP0273116A3 (en) 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonococcal and meningococcal polypeptides, vaccines and diagnostics
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
NL8803111A (nl) 1988-12-19 1990-07-16 Nederlanden Staat Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
ATE120093T1 (de) 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DK0504202T3 (da) * 1989-12-14 1995-10-02 Ca Nat Research Council Forbedret meningokok-polysaccharid-konjugat vaccine
CU22302A1 (es) 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
EP0467714A1 (en) 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ATE174625T1 (de) 1991-03-14 1999-01-15 Imclone Systems Inc Rekombinante hybride porinepitope
JP3368902B2 (ja) 1992-03-02 2003-01-20 カイロン エセ．ピー．アー． ワクチンおよび診断に有用なＨｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉタンパク質
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
ES2108278T3 (es) 1992-06-25 1997-12-16 Smithkline Beecham Biolog Composicion de vacuna con coadyuvantes.
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6165747A (en) 1993-12-30 2000-12-26 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
FR2720408B1 (fr) 1994-05-31 1996-08-14 Pasteur Merieux Serums Vacc Fragments Tbp2 de Neisseria meningitidis.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
FR2739624B1 (fr) 1995-10-10 1997-12-05 Pasteur Merieux Serums Vacc Nouvelle sous-unite tbp2 de neisseria meningitidis
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
EP1537877A3 (en) 1996-10-11 2005-08-03 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
WO1998017805A2 (en) 1996-10-24 1998-04-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, c/o Centers for Disease Control and Prevention, Technology Transfer Office Invasion associated genes from neisseria meningitidis serogroup b
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING NON-METHYLATED CpG DINUCLEOTIDES IN THE TREATMENT OF LIPOPOLYSACCHARIDE-ASSOCIATED ILLNESSES
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
ATE252596T1 (de) 1997-06-06 2003-11-15 Dynavax Tech Corp Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
DK1032674T3 (da) 1997-11-21 2007-04-10 Serono Genetics Inst Sa Chlamydia pneumoniae genomisk sekvens og polypeptider, fragmenter deraf og anvendelser deraf, især til diagnosen, forebyggelsen og behandlingen af infektion
WO1999028475A2 (en) 1997-11-28 1999-06-10 Genset Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
EP2278011A3 (en) 1998-01-14 2012-03-07 Novartis Vaccines and Diagnostics S.r.l. Neisseria meningitidis antigens
CN1198937C (zh) 1998-01-30 2005-04-27 第一三得利制药株式会社 利用辅助肽制造肽的方法
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
AU761780B2 (en) 1998-05-01 2003-06-12 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
MXPA01003557A (es) * 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
EP2266604A3 (en) 1998-10-16 2011-05-11 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
CA2347849C (en) * 1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
DE60038166T2 (de) 1999-03-19 2009-03-12 Glaxosmithkline Biologicals S.A., Rixensart Impfstoff gegen bakterielle antigene
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
AU780308B2 (en) 1999-04-30 2005-03-17 J. Craig Venter Institute, Inc. Neisseria genomic sequences and methods of their use
EP1228217B1 (en) 1999-04-30 2012-11-21 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
MXPA01011867A (es) 1999-05-19 2002-05-06 Chiron Spa Composiciones neisseriales de combinacion.
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
PL355232A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
CA2383413A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AU784203B2 (en) 1999-10-29 2006-02-23 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
EP2275129A3 (en) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
HUP0300696A3 (en) 2000-01-25 2004-10-28 Univ Queensland Brisbane Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha
JP4763210B2 (ja) * 2000-02-28 2011-08-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ナイセリアのタンパク質の異種発現
US20040167058A1 (en) * 2000-06-29 2004-08-26 Colgate-Palmolive Company Multi-phase clear fabric softening composition
US20040005667A1 (en) 2000-07-03 2004-01-08 Giuloi Ratti Immunisation against chlamydia pneumoniae
MX357775B (es) 2000-10-27 2018-07-20 J Craig Venter Inst Inc Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
GB0108024D0 (en) * 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
RU2323002C2 (ru) 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
ATE469915T1 (de) 2001-07-27 2010-06-15 Novartis Vaccines & Diagnostic Antikörper gegen das meningokokken adhäsin app
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP2255826B1 (en) 2002-08-02 2016-04-13 GlaxoSmithKline Biologicals S.A. Neisserial vaccine compositions comprising a combination of antigens
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
PT2353608T (pt) 2002-10-11 2020-03-11 Novartis Vaccines And Diagnostics S R L Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2512917A1 (en) 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methods for increasing neisseria protein expression
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
US20070253964A1 (en) 2003-04-16 2007-11-01 Zlotnick Gary W Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
SI1961426T1 (sl) 2003-10-02 2011-10-28 Novartis Ag Kombinirana cepiva proti meningitisu
GB0409748D0 (en) 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
TWI487535B (zh) 2004-11-30 2015-06-11 Centocor Inc 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途
RU2432962C2 (ru) 2005-01-27 2011-11-10 Чилдрен'З Хоспитал Энд Рисерч Сентер Эт Окленд Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008125985A2 (en) 2007-04-11 2008-10-23 Novartis Ag Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
JP5637848B2 (ja) 2007-06-04 2014-12-10 ノバルティス アーゲー 髄膜炎ワクチンの製剤化
EP3263591B1 (en) 2008-02-21 2019-03-27 GlaxoSmithKline Biologicals S.A. Meningococcal fhbp polypeptides
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
PT2411048T (pt) 2009-03-24 2020-07-14 Glaxosmithkline Biologicals Sa Proteína de ligação ao fator h meningocócica com adjuvante
WO2012032498A2 (en) 2010-09-10 2012-03-15 Novartis Ag Developments in meningococcal outer membrane vesicles

Also Published As

Publication number Publication date
NZ532115A (en) 2005-04-29
NZ537976A (en) 2008-03-28
US9056075B2 (en) 2015-06-16
JP2005350486A (ja) 2005-12-22
US8980277B2 (en) 2015-03-17
WO2003020756A3 (en) 2003-11-20
DK1423419T3 (da) 2011-04-04
MX336118B (es) 2016-01-08
US20140294886A1 (en) 2014-10-02
JP2014051497A (ja) 2014-03-20
CA2459816C (en) 2014-06-10
US20180169210A1 (en) 2018-06-21
PT2327719E (pt) 2014-12-02
CN101260148B (zh) 2012-05-09
CN100390196C (zh) 2008-05-28
JP5542276B2 (ja) 2014-07-09
EP1423419A2 (en) 2004-06-02
US20150273044A1 (en) 2015-10-01
JP4511832B2 (ja) 2010-07-28
ES2523365T3 (es) 2014-11-25
US9011869B2 (en) 2015-04-21
PT2360176E (pt) 2016-01-11
CY1117065T1 (el) 2017-04-05
RU2339646C2 (ru) 2008-11-27
AU2002339217B2 (en) 2008-09-04
RU2008122435A (ru) 2009-12-10
JP2010252807A (ja) 2010-11-11
CY1113218T1 (el) 2016-04-13
WO2003020756A2 (en) 2003-03-13
ATE496063T1 (de) 2011-02-15
JP2005508156A (ja) 2005-03-31
CN1582297A (zh) 2005-02-16
EP2327719A1 (en) 2011-06-01
EP2327719B1 (en) 2014-08-20
EP2360176A3 (en) 2012-01-18
DK2360176T3 (en) 2015-12-14
RU2475495C2 (ru) 2013-02-20
CA2459816A1 (en) 2003-03-13
DK2327719T3 (da) 2014-11-03
EP2360176A2 (en) 2011-08-24
US20050222385A1 (en) 2005-10-06
US20110250223A1 (en) 2011-10-13
EP2360176B1 (en) 2015-10-21
GB0121591D0 (en) 2001-10-24
AU2008234959B2 (en) 2012-05-17
RU2004110230A (ru) 2005-04-20
CN101260148A (zh) 2008-09-10
US8840907B2 (en) 2014-09-23
EP2829549A3 (en) 2015-06-03
AU2008234959A1 (en) 2008-11-13
MXPA04002216A (es) 2005-02-17
EP1423419B1 (en) 2011-01-19
DE60238993D1 (de) 2011-03-03
ES2357503T3 (es) 2011-04-27
BR0212363A (pt) 2004-08-10
EP2829549A2 (en) 2015-01-28
PT1423419E (pt) 2011-03-10
NZ547145A (en) 2008-06-30
US20120195919A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
ES2556770T3 (es) Expresión híbrida y en tándem de proteínas procedentes de Neisseria
Lee et al. EfrAB, an ABC multidrug efflux pump in Enterococcus faecalis
ES2436747T3 (es) Variantes multiples de protenia NMB 1870 de meningococo
Chorev The partial retro–inverso modification: a road traveled together
US20030044429A1 (en) Toll-like receptor 5 ligands and methods of use
CN1404487A (zh) 高纯度脂肽、脂肽胶束及其制备方法
CN102552874A (zh) 用于减少cd36表达的方法
JP2009155344A (ja) アジュバント化された抗原性髄膜炎菌性組成物
CN1261896A (zh) 诊断和预防莱姆病用的组合物的表面抗原和蛋白质
US20170190755A1 (en) Immunomodulatory compositions and methods for treating disease with modified host defense peptides
US20060134143A1 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
Miao et al. Inhibition of bacterial RNA polymerases. Peptide metabolites from the cultures of Streptomyces sp.
US5000952A (en) Polypeptide pertussis toxin vaccine
Oshima et al. Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective HC fragment (residues 855–1296) of the toxin
US20080131465A1 (en) Group a Streptococcus Crge Protein
US5719064A (en) Peptide diagnostics and therapeutics for spondyloarthropathies
AU769157B2 (en) Novel pyrrhocoricin-derived peptides, and methods of use thereof
EP1485466A2 (en) Methods for treating diseases or conditions with peptide constructs
EP0785947B1 (en) Peptides endowed with antiinflammatory activity
WO2011103458A2 (en) Compositions and methods for using and identifying antimicrobial agents
Scioli et al. New Teixobactin Analogues with a Total Lactam Ring
JP4166408B2 (ja) 新規タキキニンペプチドおよびその前駆体ポリペプチドならびにこれらをコードする遺伝子
US7015309B1 (en) Pyrrhocoricin-derived peptides, and methods of use thereof
JP5795079B2 (ja) 細胞表面で発現される抗菌ペプチド多重合複合体
US20060134126A1 (en) Peptide constructs for treating disease